Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
20091.4k citationsMarc A. Pfeffer, Emmanuel A. Burdmann et al.New England Journal of Medicineprofile →
Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition
2007828 citationsDebra F. Higgins, Kuniko Kimura et al.Journal of Clinical Investigationprofile →
Countries citing papers authored by Kai-Uwe Eckardt
Since
Specialization
Citations
This map shows the geographic impact of Kai-Uwe Eckardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kai-Uwe Eckardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kai-Uwe Eckardt more than expected).
This network shows the impact of papers produced by Kai-Uwe Eckardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kai-Uwe Eckardt. The network helps show where Kai-Uwe Eckardt may publish in the future.
Co-authorship network of co-authors of Kai-Uwe Eckardt
This figure shows the co-authorship network connecting the top 25 collaborators of Kai-Uwe Eckardt.
A scholar is included among the top collaborators of Kai-Uwe Eckardt based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Kai-Uwe Eckardt. Kai-Uwe Eckardt is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
4 of 4 papers shown
#
Work
Indexed citations
1
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease breakdown →
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.